ProKidney GAAP EPS of -$0.12 beats by $0.02, revenue of $0.22M beats by $0.18M [Seeking Alpha]
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates [Yahoo! Finance]
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference